Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04243863 · ClinicalTrials.gov registry record · Phase 1
VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers
A Phase 1 study, sponsored by Basilea Pharmaceutica.
- Completed
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
NCT04243863 is a Phase 1 study that has completed, run by Basilea Pharmaceutica. The registered enrollment target is 83 participants.
The verdict
NCT04243863, a Phase 1 study, has completed, sponsored by Basilea Pharmaceutica.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
Study Summary
This is a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-7145. In part 1, subjects will receive a single dose of VNRX-7145; in part 2 subjects will receive multiple doses of VNRX-7145 for 10 days.
Interventions
- DRUG Placebo
- DRUG VNRX-7145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2020-01-20 |
| Est. Completion | 2021-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04243863
The ClinicalTrials.gov registry entry for NCT04243863 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04243863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04243863 about?
NCT04243863 is a clinical study titled "VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers". This is a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-7145. In part 1, subjects will receive a single dose of VNRX-7145; in part 2 subjects will receive multiple doses of VNRX-7145 for 10 days.
What is the current status of trial NCT04243863?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2020-01-20. Estimated completion is 2021-04-05.
What interventions are being tested in trial NCT04243863?
The interventions under investigation include: Placebo (DRUG), VNRX-7145 (DRUG).
Who is sponsoring clinical trial NCT04243863?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.